Bristol-Myers Squibb Co 2024 SR
The report outlines Bristol Myers Squibb's 2024 sustainability and social impact performance, focusing on three pillars: advancing patient health, expanding science, and fostering an inclusive workforce. Key highlights include the launch of the ASPIRE program to improve medicine access in low- and middle-income countries and receiving SBTi validation for net-zero targets. The company achieved zero patient-level recalls and reduced drug shortages. Environmental efforts included a 55% reduction target for Scope 1 and 2 emissions by 2033 and achieving 44% renewable electricity.
Company: Bristol-Myers Squibb Co
Sector: Health Care
Country: United States
Year: 2024
Type: SR
Pages: 81
Bristol-Myers Squibb Co
Building A Better Future Report
The report outlines Bristol Myers Squibb's 2024 sustainability and social impact performance, focusing on three pillars: advancing patient health, expanding science, and fostering an inclusive workforce. Key highlights include the launch of the ASPIRE program to improve medicine access in low- and middle-income countries and receiving SBTi validation for net-zero targets. The company achieved zero patient-level recalls and reduced drug shortages. Environmental efforts included a 55% reduction target for Scope 1 and 2 emissions by 2033 and achieving 44% renewable electricity.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Jun 24, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Net Zero Target
Employees